EC Number   |
Inhibitors |
Structure |
|---|
   3.4.22.47 | 1-(3-phenylpropionyl)piperidine-3-(R,S)-carboxylic acid-[4-amino-1(S)-(benzothiazole-2-carbonyl)butyl] amide |
reversible inhibition |
   |
| 3.4.22.47 | benzamidine derivatives |
- |
|
| 3.4.22.47 | benzyl-N-[(2S)-1-[[(3S)-7-amino-1-(benzylamino)-1,2-dioxoheptan-3-yl]amino]-5-(2-methyl-2-phenylhydrazinyl)-1,5-dioxopentan-2-yl]carbamate |
i.e. KYT-36, peptide-derived, potent, bioavailable and highly selective inhibitor |
|
| 3.4.22.47 | benzyloxycarbonyl-L-phenylalanyl-L-lysyl-acyloxyketone |
- |
|
| 3.4.22.47 | benzyloxycarbonyl-L-phenylalanyl-L-lysylacyloxyketone |
the inhibitor completely abolishes osteoclastogenesis induced by Kgp |
|
| 3.4.22.47 | benzyloxycarbonyl-Phe-Lys-chloromethylketone |
i.e. z-FKck, specific for Kgp |
|
| 3.4.22.47 | carbobenzoxy-Glu(NHN(CH3)Ph)-Lys-CO-NHCH2Ph |
- |
|
| 3.4.22.47 | carbobenzoxy-Lys-Arg-CO-Lys-N-(CH3)2 |
- |
|
| 3.4.22.47 | cathepsin B inhibitor |
- |
|
| 3.4.22.47 | Chlorhexidine |
synergistic effect of Zn2+ in a 1:1 ratio of chlorhexidine and Zn2+ |
|
